Insmed Inc

INSM

$38.13

+57.29% (1 year change)

Avg closing price

Price range

Market Cap

$3.78 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$42.5 Million

Total revenue in the last quarter.

Net Income

-$61.9 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

-$2.65

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-15.63x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-54.1 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

0

The number of full time employees.

Revenue & Earnings

Balance Sheet

News

Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP)

Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP)

BRIDGEWATER, N.J., Feb. 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases...

PR Newswire PR Newswire, 17 days ago
Insmed to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021

Insmed to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021

BRIDGEWATER, N.J., Feb. 12, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare disease...

PR Newswire PR Newswire, 24 days ago
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., Feb. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,...

PR Newswire PR Newswire, about 1 month ago